BOTHELL, Wash.--(BUSINESS WIRE)--Feb. 6, 2006--Lumera Corporation (Nasdaq:LMRA), an emerging leader in the field of nanotechnology, announced today that it has executed a letter of intent with the Medical University of South Carolina to purchase its newly released ProteomicProcessor(TM) Biosensor instrument. Additionally, MUSC and Lumera announced they will co-develop a new protein chip, based on Lumera’s NanoCapture(TM) HPT technology, which will be aimed at the growing drug discovery and toxicology market. Terms of the agreement were not disclosed.
